新生儿戒断综合征的门诊药物治疗
本研究基于田纳西州医疗补助计划2009至2011年数据,回顾性分析736例确诊新生儿戒断综合征患儿,比较仅住院药物治疗与出院后继续门诊药物治疗的差异。结果显示门诊药物治疗组初始住院时间更短但总治疗时间更长,且出院后6个月内急诊就诊率更高。
要点
- 门诊药物治疗组初始住院时间更短(11天 vs 23天,P < .001)。
- 门诊药物治疗组总治疗时间更长(60天 vs 19天,aIRR 2.84,95%CI 2.31-3.52)。
- 门诊药物治疗组出院后6个月内急诊就诊次数更多(aOR 1.52,95%CI 1.06-2.17)。
核心结论
- 与仅住院治疗相比,新生儿戒断综合征门诊药物治疗与更长的治疗时间和更高的急诊利用率相关。
研究设计与样本
- 回顾性队列研究,使用2009至2011年田纳西州医疗补助计划参保婴儿的行政和生命记录数据,通过病历回顾确认新生儿戒断综合征病例并分类治疗类型。
主要发现
- 736例确诊新生儿戒断综合征患儿中,72.3%接受药物治疗,其中约一半(45.5%)出院时带门诊药物。
- 门诊药物治疗组初始住院时间更短(11天 vs 23天,P < .001)。
- 门诊药物治疗组总治疗时间更长(60天 vs 19天,调整后发病率比值比[aIRR] 2.84,95%CI 2.31-3.52)。
- 调整潜在混杂因素后,门诊药物治疗组出院后6个月内急诊就诊次数更多(调整后比值比[aOR] 1.52,95%CI 1.06-2.17)。
临床怎么用
- 对于新生儿戒断综合征患儿,选择门诊药物治疗时需权衡缩短初始住院时间与延长总治疗时间及增加急诊利用的风险。
局限性
- 本研究为回顾性队列研究,使用行政和生命记录数据,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine differences in lengths of stay, length of therapy, emergency department (ED) utilization, and hospital readmissions between infants with neonatal abstinence syndrome (NAS) treated exclusively with inpatient pharmacotherapy compared with those discharged on outpatient pharmacotherapy. STUDY DESIGN: This retrospective cohort study of infants enrolled in the Tennessee Medicaid program used administrative and vital records data from 2009 to 2011. Medical record review was used to confirm cases of NAS and classify treatment type. Negative binomial regression was used to compare length of therapy and ordinal regression was used to determine frequency of ED visits and hospital readmissions. RESULTS: Among a cohort of 736 patients with confirmed NAS, 72.3% were treated with pharmacotherapy of which approximately one-half (45.5%) were discharged home on outpatient medications. For infants discharged on outpatient pharmacotherapy, initial hospital length of stay was shorter (11 vs 23 days; P < .001) and length of therapy was longer (60 vs 19 days; adjusted incidence rate ratio [aIRR] 2.84, 95%CI 2.31-3.52). After adjusting for potential confounders, infants discharged on outpatient pharmacotherapy had a greater number of ED visits within 6 months of discharge (adjusted odds ratio [aOR] 1.52, 95% CI 1.06-2.17) compared with those treated as inpatients alone. CONCLUSIONS: Outpatient pharmacotherapy for NAS was associated with higher length of therapy and higher rates of ED utilization when compared with infants treated exclusively as inpatients. Future research should focus on improving the efficiency of NAS management while minimizing postdischarge complications.
引用
- Maalouf FI, Cooper WO, Slaughter JC, et al. Outpatient Pharmacotherapy for Neonatal Abstinence Syndrome. J Pediatr. 2018. PMID: 29754866. doi:10.1016/j.jpeds.2018.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。